NDAORALSUSPENSION
Approved
Aug 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
ALDOMET (methyldopa) by Merck & Co. is clinical pharmacology methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. First approved in 1981.
Drug data last refreshed 13h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDOMET (methyldopa) is an oral antihypertensive agent approved in 1981 that lowers blood pressure through central alpha-adrenergic receptor stimulation and metabolism to alpha-methylnorepinephrine. It is a small-molecule aromatic-aminoacid decarboxylase inhibitor indicated for hypertension management. The drug maintains cardiac output without acceleration and produces stable blood pressure reduction with minimal postural hypotension.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); brand team likely focused on defensive positioning and managed decline.
Mechanism of Action
CLINICAL PHARMACOLOGY Methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then…
Worked on ALDOMET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.